Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers

Autor:	Stefan Steurer, Ronald Simon, Thorsten Schlomm, Anna Lena Wecker, Martina Kluth, Andreas M. Luebke, Doris Höflmayer, Sarah Minner, Hartwig Huland, Christoph Fraune, Hans Heinzer, Sören Weidemann, Andreas Marx, Waldemar Wilczak, Alexander Haese, Till S. Clauditz, Claudia Hube-Magg, Guido Sauter, Katharina Möller, Georgia Makrypidi-Fraune, Sarah Bonk, Christian Bernreuther
Rok vydání:	2020
Předmět:	Male 0301 basic medicine hnRNPA1 Heterogeneous nuclear ribonucleoprotein Oncogene Proteins Fusion Heterogeneous Nuclear Ribonucleoprotein A1 Fusion gene Prostate cancer 0302 clinical medicine Risk Factors Prostate Tissue microarray Margins of Excision General Medicine Middle Aged Prognosis Immunohistochemistry Up-Regulation Treatment Outcome medicine.anatomical_structure Lymphatic Metastasis 030220 oncology & carcinogenesis Original Article Kallikreins Gene Fusion Biochemical recurrence TMPRSS2 Pathology and Forensic Medicine 03 medical and health sciences Predictive Value of Tests Biomarkers Tumor medicine Humans TMA Molecular Biology Aged Cell Proliferation Neoplasm Staging Prostatectomy business.industry Prostatic Neoplasms Cell Biology Prostate-Specific Antigen medicine.disease 030104 developmental biology Tissue Array Analysis Cancer cell Cancer research Neoplasm Grading Neoplasm Recurrence Local business
Zdroj:	Virchows Archiv
ISSN:	1432-2307 0945-6317
DOI:	10.1007/s00428-020-02834-4
Popis:	Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) is a ubiquitous RNA splicing factor that is overexpressed and prognostically relevant in various human cancer types. To study the impact of hnRNPA1 expression in prostate cancer, we analyzed a tissue microarray containing 17,747 clinical prostate cancer specimens by immunohistochemistry. hnRNPA1 was expressed in normal prostate glandular cells but often overexpressed in cancer cells. hnRNPA1 immunostaining was interpretable in 14,258 cancers and considered strong in 33.4%, moderate in 45.9%, weak in 15.3%, and negative in 5.4%. Moderate to strong hnRNPA1 immunostaining was strongly linked to adverse tumor features including high classical and quantitative Gleason score, lymph node metastasis, advanced tumor stage, positive surgical margin, and early biochemical recurrence (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52b250226d6180db5fe49d37c01a826e https://doi.org/10.1007/s00428-020-02834-4 Zobrazit plný text záznamu Full text from SpringerLink